Emergent Biosolutions Inc (EBS)

Feb 03, 2025

Emergent BioSolutions (NYSE:EBS) Trading Down 7%Here's Why - MarketBeat

Feb 03, 2025

Jan 31, 2025

Emergent BioSolutions (NYSE:EBS) Shares Down 3.9%What's Next? - MarketBeat

Jan 31, 2025

Jan 30, 2025

Where are the Opportunities in (EBS) - Stock Traders Daily

Jan 30, 2025

Jan 30, 2025

Emergent BioSolutions up 10% on HC Wainwright buy initiation - MSN

Jan 30, 2025

Jan 29, 2025

Emergent BioSolutions’ CEO Sold $11 Million worth of stock before error in Baltimore went public - WBAL Radio

Jan 29, 2025

Jan 26, 2025

Emergent BioSolutions Inc. to Host Earnings Call - ACCESS Newswire

Jan 26, 2025

Jan 25, 2025

Emergent BioSolutions (NYSE:EBS) Stock Rating Lowered by StockNews.com - MarketBeat

Jan 25, 2025

Jan 24, 2025

Emergent BioSolutions Inc (EBS) Stock Price Up 3.4% on Jan 24 - GuruFocus.com

Jan 24, 2025

Jan 23, 2025

Emergent BioSolutions (NYSE:EBS) Trading 7.2% HigherTime to Buy? - MarketBeat

Jan 23, 2025

Jan 23, 2025

Emergent seeking to reverse fortunes and become a major overdose treatment player - Pharmaceutical Technology

Jan 23, 2025

Jan 22, 2025

There's No Escaping Emergent BioSolutions Inc.'s (NYSE:EBS) Muted Revenues Despite A 26% Share Price Rise - Simply Wall St

Jan 22, 2025

Jan 21, 2025

Emergent BioSolutions stock reaffirms buy rating on contract modification - MSN

Jan 21, 2025

Jan 21, 2025

Emergent BioSolutions (NYSE:EBS) Earns "Buy" Rating from HC Wainwright - MarketBeat

Jan 21, 2025

Jan 21, 2025

Emergent BioSolutions stock reaffirms buy rating on contract modification By Investing.com - Investing.com UK

Jan 21, 2025

Jan 21, 2025

The Analyst Verdict: Emergent BioSolutions In The Eyes Of 4 Experts - Benzinga

Jan 21, 2025

Jan 20, 2025

EBS (Emergent BioSolutions) Revenue : $1,094 Mil (TTM As of Sep. 2024) - GuruFocus.com

Jan 20, 2025

Jan 20, 2025

Blood Plasma Market Growing at 4.07% CAGR to Hit 42.0 Billion USD by 2032 | Emergent BioSolutions, ADMA - EIN News

Jan 20, 2025

Jan 20, 2025

Barclays PLC Has $329,000 Stake in Emergent BioSolutions Inc. (NYSE:EBS) - MarketBeat

Jan 20, 2025

Jan 20, 2025

EBS (Emergent BioSolutions) Free Cash Flow : $138 Mil (TTM As of Sep. 2024) - GuruFocus.com

Jan 20, 2025

Jan 20, 2025

Emergent BioSolutions gains exclusive commercial rights to KLOXXADO - MSN

Jan 20, 2025

Jan 16, 2025

Africa CDC Launches Groundbreaking Pan-African Mpox Treatment Trial in DRC - StockTitan

Jan 16, 2025

Jan 15, 2025

Emergent BioSolutions presents at healthcare conference By Investing.com - Investing.com Australia

Jan 15, 2025

Jan 15, 2025

Emergent BioSolutions Outlines Growth at J.P. Morgan Conference - TipRanks

Jan 15, 2025

Jan 15, 2025

Emergent BioSolutions presents at healthcare conference - Investing.com

Jan 15, 2025

Jan 15, 2025

Rep. Steve Cohen Sells Emergent BioSolutions Inc. (NYSE:EBS) Stock - MarketBeat

Jan 15, 2025

Jan 14, 2025

StockNews.com Upgrades Emergent BioSolutions (NYSE:EBS) to Buy - MarketBeat

Jan 14, 2025

Jan 14, 2025

Emergent secures rights to KLOXXADO nasal spray By Investing.com - Investing.com Canada

Jan 14, 2025

Jan 14, 2025

Hikma announces exclusive commercial partnership with Emergent BioSolutions for KLOXXADO® (naloxone HCl) nasal spray 8 mg - The Malaysian Reserve

Jan 14, 2025

Jan 14, 2025

Hikma announces exclusive commercial partnership with Emergent B - GuruFocus.com

Jan 14, 2025

Jan 14, 2025

Emergent secures rights to KLOXXADO nasal spray - Investing.com

Jan 14, 2025

Jan 14, 2025

Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals - The Manila Times

Jan 14, 2025

Jan 14, 2025

Emergent BioSolutions: Stock Is A Likely Winner In 2025 (NYSE:EBS) - Seeking Alpha

Jan 14, 2025

Jan 14, 2025

Hikma Partners with Emergent BioSolutions for KLOXXADO® Opioid Overdose Treatment Distribution - StockTitan

Jan 14, 2025

Jan 14, 2025

Emergent BioSolutions Expands Overdose Treatment Portfolio with Exclusive KLOXXADO Rights - StockTitan

Jan 14, 2025

Jan 13, 2025

Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola - The Manila Times

Jan 13, 2025

Jan 13, 2025

Emergent BioSolutions Secures $16.7M BARDA Contract for Ebola Treatment Development - StockTitan

Jan 13, 2025

Jan 11, 2025

Emergent BioSolutions exercises $20M option to supply DoD with BioThrax - MSN

Jan 11, 2025

Jan 10, 2025

HC Wainwright Reiterates Buy Rating for Emergent BioSolutions (NYSE:EBS) - MarketBeat

Jan 10, 2025

Jan 09, 2025

Those who invested in Emergent BioSolutions (NYSE:EBS) a year ago are up 365% - Yahoo Finance

Jan 09, 2025

Jan 08, 2025

Emergent BioSolutions Receives $20 Million Contract to Supply Anthrax Vaccine to US Military - Marketscreener.com

Jan 08, 2025

Jan 08, 2025

Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed) - The Manila Times

Jan 08, 2025

Jan 08, 2025

Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 - Marketscreener.com

Jan 08, 2025

Jan 08, 2025

Emergent BioSolutions Secures $20M Defense Contract for Anthrax Vaccine BioThrax - StockTitan

Jan 08, 2025

Dec 31, 2024

Emergent Stock Skyrockets 251% YTD: How to Play the Stock? - MSN

Dec 31, 2024

Dec 31, 2024

The 13% return this week takes Emergent BioSolutions' (NYSE:EBS) shareholders one-year gains to 285% - Simply Wall St

Dec 31, 2024

Dec 31, 2024

HC Wainwright & Co. Initiates Coverage of Emergent BioSolutions (EBS) with Buy Recommendation - MSN

Dec 31, 2024